Hyperglycaemia News and Research

RSS

Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glucose lowering may significantly reduce the risk of ischaemic heart disease in at-risk middle-aged people with Type 2 diabetes, a post-hoc analysis of the ACCORD trial suggests.

5 Sep 2014

Type 2 diabetes adds to hospital mortality risk in bipolar patients

Type 2 diabetes is a major contributor to mortality in patients with bipolar disorder who are admitted to general hospitals, a study shows.

3 Sep 2014

Insulin pumps better than injections for glycaemic control in Type 2 diabetes

Patients with Type 2 diabetes achieve better glycaemic control with insulin pumps than multiple insulin injections, show the findings of the OpT2mise randomised trial.

4 Jul 2014

Glycaemic control crucial in first years after diabetes diagnosis

The largest deterioration in glycaemic control among patients with newly diagnosed Type 2 diabetes occurs in the first 2 years after diagnosis, research shows.

5 Jun 2014

Metabolic syndrome linked to BP variability

Blood pressure variability is increased in patients with the metabolic syndrome, shows an analysis of NHANES III data.

19 May 2014

Morbidity following liver transplant is highest among obese patients with diabetes

Researchers from New Zealand report that morbidity following liver transplant is highest among obese patients with diabetes, but these risk factors do not influence post-transplant survival.

24 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Linagliptin as monotherapy or in combination with metformin reduces blood glucose levels in T2D patients

Boehringer Ingelheim and Eli Lilly and Company today announced new data from a Phase IV study evaluating linagliptin (5 mg) as monotherapy and in combination with metformin (1500 or 2000 mg) in treatment-naive adults with newly diagnosed (<12 months) uncontrolled Type 2 Diabetes.

4 Dec 2013

Study finds few beneficial effects of metformin drug for cardiovascular disease in people without diabetes

Despite high expectations for the commonly used diabetes drug metformin to improve risk factors for heart disease in people without diabetes, few beneficial effects have been found in a randomised trial of patients with established cardiovascular disease, published in The Lancet Diabetes & Endocrinology.

7 Nov 2013

Study: Type 2 diabetic patients treated with DPP-4 linagliptin experience reductions in blood glucose levels

Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo.

17 Aug 2013

Individualised care can make huge difference in older patients with type 2 diabetes

More than a quarter of over 70s with type 2 diabetes could benefit simply from improving communication and education in the clinic, new research has revealed. A study led by the University of Exeter Medical School and published in The Lancet found that 27 percent achieved better glycaemic control through individualised care alone.

9 Jul 2013

Analysis of anonymized web log data on drugs could be used as early warning system

The authors base their findings on an analysis of the anonymised search logs of millions of US web users, who agreed to install a browser add-on and share their online searches with Microsoft throughout 2010.

7 Mar 2013

Statins: cardiovascular benefits outweigh diabetes risk

The benefits of taking statins to reduce the risk of cardiovascular disease outweigh the increased risk of developing diabetes experienced by some patients who take these cholesterol-lowering drugs, according to an Article published Online First in The Lancet.

10 Aug 2012

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Diabetes is the number 1 cause of neuropathy, which is a very common condition in itself. In fact, up to half of all neuropathy is caused by diabetes, although other people can get the condition as well.

25 Jun 2012

Ancient berry could protect against diabetic retinopathy

The ancient Tibetan goji berry could help fight blindness caused by long-term diabetes according to studies conducted by University of Sydney researchers.

5 Jun 2012

Death prediction for patients with pneumonia and raised glucose levels

Raised blood sugar (glucose) levels on admission to hospital can predict deaths in patients with community acquired pneumonia but without pre-existing diabetes, finds a study published on bmj.com today.

30 May 2012

Intensive glycaemic control may negatively affect a person's quality of life

Research published in The Cochrane Library found that the risk of death and cardiovascular disease, such as stroke, was unchanged whether glucose control was intense or conventional.

1 Aug 2011

New positive data on Generex Oral-lyn published in Diabetes, Obesity and Metabolism

Generex Biotechnology Corporation announced today that the peer-reviewed scientific journal Diabetes, Obesity and Metabolism has published new positive data in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

13 Dec 2010

Generex presents study results of Oral-lyn insulin spray at EASD Annual Meeting

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it is presenting study results at the 46th Annual Meeting of the European Association for the Study of Diabetes being held in Stockholm, Sweden, 20 - 24 September, 2010.

23 Sep 2010

Patients with hyperglycaemia during acute illness have increased risk of developing diabetes: Researchers

Hyperglycemia during critical illness may be used as a warning of future diabetes. Researchers writing in BioMed Central's open access journal Critical Care have found a significant association between acute illness complicated with hyperglycaemia and the future development of type II diabetes or glucose intolerance.

8 Jul 2010